Clinics in Dermatology 1991: Vol 9 Index

17 Pages·1991·4.4 MB·English

Subject Index
A diagnosis of, 209 Allografts, cultured epidermal,
A antigen, in vascular neoplasms, 245- Acrodermatitis enteropathica, in characterization of, 578-579
246 pediatric AIDS, 62 Alopecia areata, dermatitis herpetiformis
ABO blood group antigens, in vascular Actin monoclonal antibody, in vascular associated with, 348, 356
neoplasms, 245-246 neoplasms, 244 Aluminum sulfate sticks, HIV safety
Acantholytic herpetiform dermatitis, Actinomyces israelii, identification of, 211 precautions and, 34
dermatitis herpetiformis related Actinomycin D, for Kaposi’s sarcoma, 43 Amalgam, in iatrogenically acquired skin
to, 361 Acyclovir (Zovirax) disease, 170-171
Acantholytic squamous cell carcinoma for herpes simplex virus lesions, 61, 80 Amelanotic melanoma, electron
differential diagnosis of, 244 for herpes zoster infection, 61, 81-82 microscopy in diagnosis of, 116
epithelial membrane antigen in, 249 in pregnancy, 436 Amiodarone, in iatrogenically acquired
Accidental exposure, HIV safety for varicella zoster infection, 61 skin disease, 160
precautions and, 35 resistance to, 80 Amkicin, for mycobacterial skin
Acetretin, in pregnancy, 436 Addison’s disease, dermatitis infections, 68
Acetylcholine, imbalance of, in atopic herpetiformis associated with, Amphotericin B (fungizone) for
dermatitis, 49 348, 352 coccidiomycosis, 67
Acne therapy, in pregnancy, 436, 442-443 Adenocarcinoma, therapeutic implants for disseminated cryptococcosis, 66
Acquired immunodeficiency syndrome for, 562 for disseminated histoplasmosis, 66
(AIDS) Adenoid squamous cell carcinoma for paracoccidiomycosis, 67
antiretroviral therapy for, 13-24 differential diagnosis of, 244 for severe pharyngitis, 65
atopic dermatitis-like eruptions in, 49- epithelial membrane antigen in, 249 Ampicillin, in pregnancy, 436
50 Adriamycin, see Doxorubicin Ampligen, in antiretroviral therapy, 21
bacillary angiomatosis in, 75-76 hydrochloride Amyloidosis, electron microscopy in
in children, 59-62 AE1 monoclonal antibody, in spindle cell diagnosis of, 116
colony-stimulating factors for, 527-528 tumor evaluation, 218 Ancef, see Cefazolin
dermatitis herpetiformis in, 356 AE3 monoclonal antibody, in spindle cell Anemia
flow cytometry of, 152 tumor evaluation, 218 dermatitis herpetiformis with, 348
fungal and mycobacterial skin Aerobacter aerogenes Kaposi’s sarcoma with, 41
infections in, 65-68 ciclopirox against, 473 in prediction of progression of
herpes virus infections in, 79-83 clotrimazole against, 473 asymptomatic HIV-1 infection to
Kaposi’s sarcoma in, 39-43 miconazole against, 473 AIDS, 4
neoplastic changes in, 95-98 Aerobacter cloacae Angiokeratoma, bacillary angiomatosis
pathology of HIV-related skin disease, ciclopirox against, 473 differentiated from, 76
95-108 clotrimazole against, 473 Angioma, Kaposi’s sarcoma resemblance
psoriasis and Reiters syndrome in, miconazole against, 473 to, 42
53-57 Africa Angiomatoid fibrous histiocytoma,
pruritis in, 111-113 herpes simplex virus infection with differential diagnosis of, 244
safety precautions in, 31-37 AIDS in, 79-80 Angiosarcoma, epithelioid
seborrheic dermatitis-like eruptions in, herpes zoster virus with AIDS in, 81 in AIDS
49-50 Kaposi's sarcoma in, 39-40, 42 of head and neck, Kaposi’s sarcoma
serologic and immunologic markers in AIDS, see Acquired immunodeficiency resemblance to, 42
course of, 1-5 syndrome pathology of, 98
syphilis in the presence of, 71-73 AIDS-related complex (ARC), dermatitis categorization of, 218
warts and molluscum contagiosum in, herpetiformis associated with, 348 Class II histocompatibility antigens in,
87-91 Albinism, electron microscopy in 247
Acrodermatitis chronica atrophicans, diagnosis of, 116 cytokeratins in, 248
© 1992 by Elsevier Science Publishing Co., Inc.- 0738-081x/92/$5.00
596 SUBJECT INDEX Clinics in Dermatology
1992;9:595-611
differential diagnosis of, 244 Antiretroviral therapy, for HIV-1 Austria, dermatitis herpetiformis in, 342—
idealized immunophenotypes of, 219 biological response modifiers, 20 343
Ulex europaeus I agglutinin in, 246 2’,3’-dideoxyadenosine, 18 Autoantibodies, in dermatitis
vimentin in, 249 2’,3’-dideoxycytidine, 18 herpetiformis, 301-302
von Willebrand factor antigen in, 245 2’,3’-dideoxyinosine, 18-19 Autografts, cultured epidermal,
Animal fibers, in iatrogenically acquired future trends in, 23-24 characterization of, 578-579
skin disease, 170 inhibitors of cell entry, binding, and Autoimmune diseases
Anspor, see Cephradine fusion, 13-15 dermatitis herpetiformis association
Anthralin, in pregnancy, 436 oligodeoxynucleotides, 19 with, 347-356
Anti-arrythmic medications, in peptide T, 15-16 flow cytometry of, 154-155
iatrogenically acquired skin polyanionic compounds, 15 Autoimmune hemolytic anemia,
disease, 161 post-translational modification dermatitis herpetiformis
Antibacterial agents, topical, for burns, inhibitors, 19-20 associated with, 348, 356
455-456 glycosylation inhibitors, 20 Autolytic debridement, characterization
Antibiotics protease inhibitors, 20 of, 587-588
for burns, 454-455 recombinant soluble CD4, 13-15, 24 Axillae, in HIV-associated seborrheic
for dermatitis herpetiformis, 390 reverse transcriptase inhibitors, 16, 18— dermatitis, 50
in iatrogenically acquired skin disease, 19 Azidothymidine (AZT, retrovir,
161 azidothymidine, 16-17, 21 zidovudine)
Antibodies dideoxynucleoside analogs, 16-17 for AIDS, 67
in dermatitis herpetiformis, 300-302 phosphonoformate, 16 in antiretroviral therapy, 16-17, 21-23
in malignant melanoma, 235-239 translational arrest inducers, 19 2’,3’-dideoxycytidine alternated with,
in spindle cell tumor evaluation, 218- Antiseptic ointments, in iatrogenically 24
224 acquired skin disease, 161 glucosidase inhibitors with, 24
in vascular neoplasms, 243-245, 247— Antiseptics, in pregnancy, 436, 445-446 for HIV-associated psoriasis, 56
249 a-Antitrypsin, as practical in vivo activity of, 21-22
o-Antichymotrypsin immunocytochemical stain, for Kaposi’s sarcoma, 43
polyclonal antibody to, 218-219 characterization of, 117 for pediatric AIDS, 61-62
as practical immunocytochemical Antivirals side effects of, 22-23
stain, characterization of, 117 in pregnancy, 436 structure of, 17
Antifungals teratogenicity of, 438-439 symptomless AIDS patients treated
in pregnancy, 436 therapeutic indications for, 438 with, 1
teratogenicity of, 439-440 Aprotinin, see Trasylol AZT, see Azidothymidine
therapeutic indications for, 439 Aqueous Penicillin G, for syphilis
Antigenemia, in prediction of associated with AIDS, 73 B
progression of asymptomatic Arachidonic acid, in ear edema assay, Bacillary (epithelioid) angiomatosis, in
HIV-1 infection to AIDS, 1-5 474-475 A
Antihistamines Arborization, in verruca vulgaris, 99 in children, 61
for HIV-associated pruritis, 113 ARC, see AIDS-related complex differential diagnosis of, 76
in pregnancy Argyria disease course of, 76
teratogenicity of, 436-437 electron microscopy in diagnosis of, etiology of, 76
therapeutic indications for, 116 histopathology of, 75-76
435-436 ocupationally-acquired foreign bodies Kaposi’s sarcoma resemblance
Anti-inflammatory medications, in as cause of, 169, 172 to, 42
iatrogenically acquired skin Aristopan parenteral, see Triamcinolone morphology of, 75-76
disease, 160 Arthritis pathology of, 98
Antimalarial drugs Kaposi’s sarcoma associated with, 41 pleomorphic bacilli in, 207
in iatrogenically acquired skin disease, medications, in iatrogenically acquired treatment of, 76
161 skin disease, 160 Bacillus spp.
in pregnancy, 436 Aspartic proteinase, in antiretroviral ciclopirox against, 473
therapeutic indications for, 441 therapy, 20 clotrimazole against, 473
Antimicrobials Aspergillus spp., identification of, 211 miconazole against, 473
for atopic dermatitis, 49 Atopic dermatitis Bacitracin, in pregnancy, 436
for burns, 454~455 in dermatitis herpetiformis, 365-366, Backscattered electron imaging
in pregnancy, 436, 443 380 (BEI), of cutaneous foreign bodies,
teratogenicity of, 437-438 in HIV-associated pruritis, 112 158-159
therapeutic indications for, 437 in HIV-infected patients, 49-50 Bacteremia, staphylococcal, in
Antiparasitics in pediatric AIDS, 61 atopic dermatitis, 49
teratogenicity of, 440-441 Atrophic gastritis, in dermatitis Bacterial folliculitis, in AIDS,
therapeutic indications for, 440 herpetiformis, 351, 417 pathology of, 107-108
Antipruritics, topical, for HIV-associated Auranofin, structure of, 536 Bacterial infection, in pediatric
pruritis, 113 Aurothioglucose, structure of, 536 AIDS, 60-61
Clinics in Dermatology SUBJECT INDEX 597
1992;9:595-611
Bactrim, see Trimethoprim- Bullous dermatitis for cutaneous pain, 498
sulfamethoxazole electron microscopy in diagnosis of, for diabetic neuropathy, 499-500
B antigen, in vascular neoplasms, 245-246 116 for postherpetic neuralgia, 498-499
Basal cell carcinoma, in AIDS, pathology in HIV-associated pruritis, 112 for pruritis, 500
of, 98 idealized direct immmunofluorescent for psoriasis, 500-501
B-cell lymphoma findings in, 116 for skin disease, 4 8
differential diagnosis of, 230 Bullous pemphigoid pharmacology and chemistry of, 497-
gene rearrangement analysis in, 123- in dermatitis herpetiformis, 306, 362- 498
124 363, 366 Carcinoembryonic antigen (CEA)
histological appearance of, 230 in Kaposi's sarcoma, 41 in immunocytochemical staining, 117
immunotyping of, 268, 270 Burkitt’s lymphoma, Kaposi’s sarcoma in intraepithelial pagetoid neoplasm,
BCNU, see Carmustine associated with, 40 258
BEI, see Backscattered electron imaging Burns, pharmacologic treatment of in Paget’s disease, 256
Benzathine penicillin (bicillin), for analgesia and anti-inflammatory in vascular neoplasms, 248
syphilis associated with AIDS, 72- treatment, 453-454 Carmustine (BCNU)
73 immunotherapy, 456-457 for Kaposi’s sarcoma, 43
Benzodiazepines, in burn therapy, 453 nutrition, 454 in pregnancy, 436
Benzoyl peroxide, in pregnancy, 436 replacement therapy, 453 in therapeutic implants, 563-564, 567
Ber-H2 antigen, in immunophenotyping, systemic antimicrobials, 454-455 Castanospermine, in antiretroviral
264 topical antibacterial agents, 455-456 therapy, 20
Berylliosis, ocupationally-acquired BW200 antibody, in vascular neoplasms, Catecholamines, imbalance of, in atopic
foreign bodies as cause of, 169, 245 dermatitis, 49
172-173 Cat scratch disease, diagnosis of, 207
Beryllium, in iatrogenically acquired skin Cc Caustic agents, for condyloma
disease, 169, 172-173 C3 deposits, in dermatitis herpetiformis, acuminatum removal, 90
Betadine, see Povidone-iodone 275, 300, 318, 330, 349, 378, 384 CD series antigens, in
Betamethasone, in pregnancy, 436 C5-C9 membrane attack complex, in immunophenotyping, 262-270
Bicillin, see Benzathine penicillin dermatitis herpetiformis, 318 CD4, recombinant soluble, in
Bifonazole, fungicidal activity of, 472 C41 antibody, in vascular neoplasms, 244 antiretroviral therapy, 13-15, 24
Biohazardous waste, HIV safety Cactus spines, in iatrogenically acquired CDpositive lymphocytes, peripheral
precautions and, 34-36 skin disease, 170 blood, decreased number of in
Biological response modifiers, in Cadmium, injected, in iatrogenically prediction of progression of
antiretroviral therapy, 20-21 acquired skin disease, 165 asymptomatic HIV-1 infection to
Biological skin equivalents, Calcium alginate, in osmotic AIDS, 1-5
characterization of, 578 debridement, 588 CD8-positive lymphocytes, in AIDS, 3
Blacks CAM 5.2 monoclonal antibody, in spindle CEA, see Carcinoembryonic antigen
dermatitis herpetiformis in, 375 cell tumor evaluation, 218 Ceclor, see Cefaclor
Kaposi’s sarcoma in, 39-40 Camphor, in pregnancy, 436, 446 Cefaclor (Ceclor), structure of, 463
Blastomyces dermatidis infection, in AIDS, Cancer Cefadroxil (Duricef, Ultracef), structure
67 cytokine therapy for, 523-529 of, 462
Blastomyces spp., identification of, 211 in dermatitis herpetiformis, 369-372 Cefamandole, structure of, 462
Blastomycosis, in AIDS, 67 electron microscopy in diagnosis of, Cefazolin (Ancef, Kefzol), structure of,
Bleaching creams, in iatrogenically 116 461
acquired skin disease, 166 therapeutic implants for, 562 Cefonicid (Monocid), structure of, 466
Blenoxane, see Bleomycin Cancer biology, in situ hybridization Cefotaxime (Claforan), structure of, 464
Bleomycin (Blenoxane) applications in, 132 Cefotan, see Cefotetan
for Kaposi’s sarcoma, 42-43 Candida albicans infection Cefotetan (Cefotan), structure of, 463
in therapeutic implants, 563-564 in AIDS Cefoxitin (Mefoxin), structure of, 462
for verrucae vulgaris, 91 in children, 60 Cefprozil (Cefzil), structure of, 463
Bone marrow transplantation, colony- condyloma acuminatum and, 90 Ceftazidime (Fortaz, Tazicef, Tazidime),
stimulating factors used during, pathology of, 1, 65, 102 structure of, 464
528 seborrheic dermatitis and, 50 Ceftizox, see Ceftizoxime
Borelia diseases, diagnosis of, 209 identification of, 211 Ceftizoxime (Ceftizox), structure of, 464
Boric acid, in pregnancy, 436, 446 Candida tropicalis, identification of, 211 Ceftriaxone (Rocephin)
Bowenoid actinic keratosis, histologic Candidemia, in AIDS, 1, 65 structure of, 464
diagnosis of, 256 Candidosis, in pediatric AIDS, 60 for syphilis associated with AIDS, 73
Bowen's disease, histologic diagnosis of, Cantharadin Cefuroxime (Ceftin, Kefurox, Zinacef),
256 for molluscum contagiosum, 89 structure of, 462
Brain, herpes simplex virus lesions of, 80 in pregnancy, 436 Cefzil, see Cefprozil
Brazil, AIDS in, 67-68 Capsaicin Celiac disease
Bromide, in dermatitis herpetiformis, 319 dosage, adininistration, and adverse dermatitis herpetiformis associated
Brompheniramine, in pregnancy, 436 effects of, 501 with, 335-338, 347-353, 356, 380
598 SUBJECT INDEX Clinics in Dermatology
1992;9:595-611
kinetics of changes in, 307 herpes simplex virus infection, 61 implants, 563-564, 567
Cellular angiolipoma, differential herpes zoster infection, 61 Claforan, see Cefotaxime
diagnosis of, 244 human papillomavirus infection, 61 Clindamycin, in pregnancy, 436
Cellulitis, in pediatric AIDS, 60 molluscum contagiosum, 61 Clofazimine, in iatrogenically acquired
Cephalexin (Keflex), structure of, 461 varicella zoster infection, 61 skin disease, 161
Cephalosporin C, structure of, 460 inflammatory skin disorders in Clonal seborrheic keratosis, histologic
Cephalosporin nucleus, structure of, 460 atopic dermatitis, 61 diagnosis of, 258
Cephalosporins drug eruptions, 62 Clotrimazole (Lotrimin)
adverse effects of, 467 Kaposi’s sarcoma, 39-40, 62 antibacterial activity of, 473
comparative clinical efficacy of in nutritional deficiencies, 62 fungicidal activity of, 472
dermatologic infections, 465-466 psoriasis, 62 in pediatric AIDS, 60
history of development of, 459-460 seborrheic dermatitis, 61 in pregnancy, 436
classification by “generation”, 460 vasculitis, 62 Cloxacillin, in pregnancy, 436
first-generation cephalosporins, 461 skin manifestations of HIV-1 infection CMV, see Cytomegalovirus
fourth-generation cephalosporins, in, 59-62 CO, laser therapy
462 timeframe for development of AIDS in, for condyloma acuminatum, 91
second-generation cephalosporins, Z for verrucae vulgaris, 91
461-462 Chlamydia trachomatis Coal tar, in pregnancy, 436
third-generation cephalosporins, condyloma acuminatum and, 90 Cobalt, injected, in iatrogenically
462 identification of, 211 acquired skin disease, 165
mechanism of action of, 462 Chloramphenicol, in pregnancy, 436 Coccidioides immitis infection, in AIDS,
microbiology of skin infections, 462- Chlorhexidine gluconate, for topical 66-67, 105
treatment of burns, 455 Colchicine, for dermatitis herpetiformis,
pharmacokinetics of, 463-465 Chloroquine 390
in pregnancy, 436 in iatrogenically acquired skin disease, Collagen
resistance to, 466-467 161 injected, in iatrogenically acquired
Cephalothin, structure of, 461 in pregnancy, 436 skin disease, 165
Cephradine (Anspor, Velosef), structure Chlorpheniramine, in pregnancy, in occlusive dressings, 578
of, 461 436 Collagenase, in enzymatic debridement,
Cetirazine Chlorpromazine 589
antihistaminic activity of, 511 for burns, 453 Colloidal iron, in intraepithelial pagetoid
anti-inflammatory activity of, 511 in iatrogenically acquired skin neoplasm assessment, 258
dosage for, 512-513 disease, 161 Colloid milium, electron microscopy in
efficacy of, 511-512 Chromatophoroma, therapeutic diagnosis of, 116
pharmacology of, 511 implants for, 562 Colon cancer, in dermatitis herpetiformis,
sedation and psychomotor effects due Chromide, in dermatitis 371
to, 512 herpetiformis, 319 Colony-stimulating factors (CSFs)
structure of, 512 Chromium, injected, in in anticancer therapy, 526-529
toxicity of, 512 iatrogenically acquired skin side effects for, 529
Chemical debridement, characterization disease, 165 Comedo extractor, for molluscum
of, 588-589 Chromogranin, as practical contagiosum removal, 89
Chemotherapeutic agent waste, HIV immunocytochemical stain, Composite culture grafts,
safety precautions and, 34 characterization of, 117 characterization of, 579
Chemotherapy Chrysiasis, medications in Condyloma acuminatum, HIV-associated
for Kaposi’s sarcoma, 42-43 induction of, 160, 163 clinical features of, 89
for mycosis fungoides, in pregnancy, Chrysotherapy, reinstatement of, complications of, 90
436, 445 544 diagnosis of, 90
myelosuppression induced by, 527 Ciclopirox olamine (Loprox) histopathology of, 90
for verrucae vulgaris, 91 antibacterial activity of, 472- treatment of, 90-91
in veterinary patients, intralesional 473 Condylomata, giant, in pediatric AIDS, 61
delivery of, 561-567 antifungal activity of, 471-472 Connective tissue disorders, electron
Childhood cicatricial pemphigoid, linear anti-inflammatory action of, microscopy in diagnosis of, 116
IgA bullous dermatosis of 475-476 Control probes, in in situ hybridization,
childhood relationship to, 398-399 mechanism of action of, 471 131
Children, HIV-1 infection in penetration of skin by, 473-475 Copper sulfate, in pregnancy, 436 .
clinical course of, 60 structure of, 472 Cornea, herpes simplex virus lesions of,
cutaneous manifestations of, 60 Ciprofloxacin, for bacillary
epidemiology of, 59-60 angiomatosis, 76 Corticosteroids
infections and infestations in Cirrhosis, primary biliary, for dermatitis herpetiformis, 390, 399
bacterial infection, 60-61 dermatitis herpetiformis for HIV-related atopic dermatitis, 49
candidosis, 60 associated with, 348 in pregnancy, 436, 443
dermatophyte infection, 60 Cisplatin (platinol), in therapeutic teratogenicity of, 422
Clinics in Dermatology SUBJECT INDEX 599
1992;9:595-611
therapeutic indications for, 441-442 diagnosis of, 205-206, 211 304-305, 307, 320, 325, 328-330,
Corynebacterium diphtheriae epidemiology of, 82 371-372, 375, 380, 384, 386, 403,
ciclopirox against, 473 Kaposi's sarcoma and, 39 405-407, 409-413, 415-418
clotrimazole against, 473 pathology of, 106-107 histopathologic findings in, 289-292
miconazole against, 473 treatment of, 83 historical perspectives on, 273-276, 403
Corynebacterium pyogenes HLA antigens in, 341-344
ciclopirox against, 473 D idealized direct immmunofluorescent
clotrimazole against, 473 Dapsone, for dermatitis herpetiformis, findings in, 116
miconazole against, 473 298, 329-330, 348, 364, 371, 380, immunogenetics in, 341-344
Cosmetic agents, in iatrogenically 389, 403-405, 415-417 immunopathology of, 295-307
acquired skin disease, 164-168 ddA, see 2’,3’-Dideoxyadenosine kidney disease and, 347-349
Cryotherapy ddC, see 2’,3’-Dideoxycytidine linear IgA bullous dermatosis of
for condyloma acuminatum, 91 ddI, see 2’,3’-Dideoxyinosine adults, 383-390
HIV safety precautions and, 34 Debridement liver disease and, 349-350
for Kaposi’s sarcoma, 42-43 autolytic, 587-588 lupus erythematosus and, 363-365, 380
for molluscum contagiosum, 89 chemical, 588-589 lymphoma and, 369-371
for verrucae vulgaris, 91 enzymatic, 589-590 malignant disease in, 369-372
Cryptococcus neoformans infection in maggot, 590 overlapping cutaneous disorders
AIDS, 66, 89, 104 mechanical, 586-588 related to, 361-366
identification of, 211 osmotic, 588 pathogenesis of, 313-320
Cryptosporidiosis, in pediatric AIDS, 60 surgical, 586 pemphigus and, 361-362
Curettage types of, 585-586 pernicious anemia and, 350-351
for condyloma acuminatum, 91 vaporization, 586 polymyositis and, 352
for molluscum contagiosum, 89 Decarbazine (DTIC), for Kaposi’s Raynaud’s phenomenon and, 353
Cutaneous T-cell lymphoma sarcoma, 43 rheumatoid arthritis and, 353-354
flow cytometry of, 153-154 Deodorants, in iatrogenically acquired Sjégren’s syndrome and, 354
gene rearrangement analysis in, 121- skin disease, 166 splenic atrophy and, 351-352
122, 125 2’-Deoxycytidine, structure of, 17 therapy for, 403-407
immunophenotyping of, 263-264 2’-Deoxyinosine, structure of, 17 thyroid disease and, 354-355, 380
response to therapy for, 154 Deoxynojirimycin, in antiretroviral ulcerative colitis and, 355
ultrastructural morphometry in therapy, 20 vitiligo and, 355-356, 380
diagnosis of, 187-188, 192-193, 2’-Deoxythymidine, structure of, 17 Dermatofibroma, Kaposi’s sarcoma
196-198 Deposition disorders, electron resemblance to, 42
Cutaneous ulcers, debridement of, 585— microscopy in diagnosis of, 116 Dermatofibrosarcoma protruberans
590 Dermabrasion fraises and brushes, HIV categorization of, 217-218
Cutis laxa, electron microscopy in safety precautions and, 34 evaluation of, 217-218
diagnosis of, 116 Dermal nerve sheath myxoma, Dermatologics, clinical development of
Cyclic neutropenia, colony-stimulating evaluation of, 221 general structure of clinical
factors for, 528-529 Dermatitis herpetiformis development program, 425-426
Cyclizine, in pregnancy, 436 Addison’s disease and, 352 beyond phase 3, 426
Cyclosporine (Sandimmune), for HIV- atopic dermatitis and, 365 phase 1, 424-425
associated psoriasis, 56 autoimmune diseases and, 347-356 phase 2, 424-425
Cyclosporine A bullous pemphigoid and, 362-363 phase 3, 424-426
clinical trials of, 515-519 celiac disease and, 347, 380 historical perspective on, 423-424
drugs interacting with, 520 childhood key elements in design and
guidelines for, 519-520 clinical features of, 376-378 progression of a clinical
pharmacology and mechanism of diseases associated with, 379-380 development program
action of, 515 differential diagnosis of, 378-379 defining program, 426-427
Cytogenetics, in situ hybridization histopathology of, 378 developing protocols and case
applications in, 132 immunofluorescence of, 378 report forms, 428
Cytokeratin monoclonal antibody pathogenesis of, 375-377 documenting clinical development
in immunocytochemical staining, 117 prognosis for, 380 plan, 427
in malignant melanoma, 235-237, 239 treatment of, 380 engaging FDA, 427
in spindle cell tumor evaluation, 218- clinical features of, 279-280, 376-378 writing label, 426
221 course of, 280 Dermatomyositis, dermatitis
in vascular neoplasms, 244, 248 dermatomyositis and, 352 herpetiformis associated with,
Cytokines diabetes mellitus and, 352-353, 380 348, 352
in anticancer therapy, 523-529 differential diagnosis of, 280 Dermatopathology techniques, new,
in atopic dermatitis, 49 drugs for, 403-405, 407 overview of, 115-117
in dermatitis herpetiformis, 314 familial, 335-338 Dermatophyte infections, in AIDS, 60, 65,
Cytomegalovirus (CMV), in AIDS gastrointestinal association in, 325-330 102
clinical features of, 82-83 gluten-free diet for, 295, 297-298, 301, Desmin monoclonal antibody
600 SUBJECT INDEX Clinics in Dermatology
1992;9:595-611
in immunocytochemical staining, 117 Drug eruptions, in AIDS patients Enteropathy-associated T-cell
in spindle cell tumor evaluation, 218, in children, 62 lymphomas, in dermatitis
223 HIV-associated pruritis and, 112 herpetiformis, 370
in vascular neoplasms, 248 superficial perivascular dermatitis Environmental Protection Agency (EPA)
Desmoplastic malignant melanoma and, 101 biohazardous waste standards of, 34
categorization of, 218 Drug pigmentation, electron microscopy guidelines of for HIV safety precaution
evaluation of, 220-221 in diagnosis of, 116 during occupational exposure, 33-
Desquamation, in HIV-related atopic DTIC, see Decarbazine
dermatitis, 50 Duricef, see Cefadroxil Enzymatic debridement, characterization
Detection systems, in in situ Dyskeratosis, pagetoid, histologic of, 589-590
hybridization, 131-133 diagnosis of, 257-258 Eosinophilic granuloma, therapeutic
Developmental biology, in situ Dyskeratotic keratinocytes, in HIV- implants for, 562, 564
hybridization applications in, 132 related atopic dermatitis, 50 Eosinophilic pustular folliculitis, in HIV-
Dexamethasone, in pregnancy, 436 associated pruritis, 112
Dextranomer beads, in osmotic E EPA, see Environmental Protection
debridement, 588 E1B protein, in dermatitis herpetiformis, Agency
Dextran sulfate, in antiretroviral therapy, 315 Epidermal growth factor (EGF)
15 E29 monoclonal antibody, in spindle cell biologic activity of, 554
Diabetes mellitus tumor evaluation, 218 source of, 554
capsaicin for neuropathy of, E92 antigen Epidermodysplasia verruciformis, warts
499-500 in Kaposi’s sarcoma, 40 mimicking, in pediatric AIDS, 61
dermatitis herpetiformis in vascular neoplasms, 245 Epidermolysis bullosa
associated with, 348, 352-353, 380 EBV, see Epstein-Barr virus electron microscopy in diagnosis of,
medications for, in Econazole, fungicidal activity of, 472 116
iatrogenically acquired skin EDXA, see Electron-dispersive X-ray idealized direct immmunofluorescent
disease, 160 analysis findings in, 116
Diaper rash, in pediatric AIDS, 60 EELS, see Electron energy loss immunofluorescence antigenic
2’,3’-Dideoxyadenosine (ddA), in spectroscopy mapping of, 182-183
antiretroviral therapy, 18 EGF, see Epidermal growth factor transmission electron microscopy of,
2’,3’-Dideoxycytidine (ddC) Elderly, timeframe for development of 183
in antiretroviral therapy, 18 AIDS in, 1 Epidermotropic carcinoma, histologic
azidothymidine alternated Electrodessication and curettage diagnosis of, 257
with, 24 for condyloma acuminatum, 91 Epithelial membrane antigen (EMA)
structure of, 17 HIV safety precautions and, 34 in immunocytochemical staining, 117
2’,3’-Dideoxyinosine (ddl) for Kaposi’s sarcoma, 42-43 in intraepithelial pagetoid neoplasm,
in antiretroviral therapy, 18-19 Electron-beam therapy, for Kaposi’s 258
structure of, 17 sarcoma, 42 in Paget’s disease, 256
Dideoxynucleoside analogs Electron-dispersive X-ray analysis in spindle cell tumors, 218-221
in antiretroviral therapy, 16-17 (EDXA), of cutaneous foreign in vascular neoplasms, 244, 248-249
structures of, 17 bodies, 158-159, 163, 168-169, 173 Epithelioid angiomatosis, see Bacillary
Diethyldithiocarbamate Electron energy loss spectroscopy (EELS), angiomatosis
(dithiocarb), in antiretroviral of cutaneous foreign bodies, 158— Epstein-Barr virus (EBV)
therapy, 21 159, 169 HIV-associated, 80
Diphenhydramine, in pregnancy, Electron microscopy, diagnostic uses of, Kaposi's sarcoma and, 39-40
436 116 lymphoma and, 96
Diphtheria vaccine, in Elemental diet, in dermatitis Eruptive xanthomas, Kaposi’s sarcoma
iatrogenically acquired skin herpetiformis, 297, 298 resemblance to, 42
disease, 160 EMA, see Epithelial membrane antigen Erysipelas, in pediatric AIDS, 60
Disinfection, HIV safety Emollients, for HIV-associated pruritis, Erysipelothrix insidiosa
precautions and, 34 113 ciclopirox against, 473
Dithiocarb, see EN-4 antibody, in vascular neoplasms, clotrimazole against, 473
Diethyldithiocarbamate 245 miconazole against, 473
DNA analysis, via flow cytometry, Encephalopathy, in pediatric AIDS, 60 Erythema chronicum migrans, diagnosis
150 Endocrinopathy, in HIV-associated of, 209
DNA probes, in in situ pruritis, 112 Erythematous plaques, in HIV-associated
hybridization, 130 Endomysial antibodies, in dermatitis seborrheic dermatitis, 50
Doxorubicin hydrochloride herpetiformis, 303-306, 328-329, Erythrocyte sedimentation rate, in
(adriamycin) 417 prediction of progression of
in immunosuppression, 555 England, dermatitis herpetiformis in, 342, asymptomatic HIV-1 infection to
for Kaposi's sarcoma, 43 344, 370 AIDS, 4
Doxyxycline, for bacillary Enterobacteriaceae, parenteral Erythroderma, in HIV-associated
angiomatosis, 76 cephalosporins against, 465 seborrheic dermatitis, 49-50
Clinics in Dermatology SUBJECT INDEX 601
1992;9:595-611
Erythromycin 337, 342-343, 370 acuminatum and, 90
for bacillary angiomatosis, 61, 76 Flow cytometry GCDFP-15, see Gross cystic disease fluid
for dermatitis herpetiformis, 390 of adult T-cell lymphoma, 154 protein-15
in pregnancy, 436 of autoimmune diseases, 154-155 Gelatin, absorbable, in iatrogenically
Erythroplasia of Queyrat, histologic of cutaneous T-cell lymphoma, 153- acquired skin disease, 162, 164
diagnosis of, 256 154 Gene mapping, in situ hybridization
Erythropoietic protoporphyria, DNA analysis and, 150 applications in, 132
dermatitis herpetiformis future applications of, 155 Gene rearrangement analysis, in
associated with, 356 of HIV, 150-153 lymphoid disease
Escherichia coli surface protein measurement and, B-cell lymphoma, 123-124
ciclopirox against, 473 149-150, 152 cutaneous T-cell lymphoma,
clotrimazole against, 473 two-color analysis in, 149-151 121-122, 125
miconazole against, 473 Flucytosine, in pregnancy, 436 follicular mucinosis, 122-123
Esophagus Fluoride, in dermatitis herpetiformis, 319 gene probes in, 124
cancer of, in dermatitis herpetiformis, 5-Fluororacil granulomatous slack skin
371 in chemical debridement, 588-589 syndrome, 122-123
herpes simplex virus lesions of, 80 in therapeutic implants, 563-565, 567 Hodgkin’s disease, 124
ESPGAN criteria, for celiac disease, 295, for verrucae vulgaris removal, 91 Ki-1-positive lymphoma, 124
300-301 Follicular mucinosis, gene rearrangement large plaque parapsoriasis,
Ethambutol, for mycobacterial skin analysis in, 122-123 122-123
infections, 68 Folliculitis, in AIDS, pathology of, 107- lymphomatoid papulosis, 123
Etoposide (VP-16), for Kaposi’s sarcoma, 108 pagetoid reticulosis, 122-123
43 Fontana—Massin stain, in intraepithelial patient-specific gene probes in,
Etretinate (Tegison) pagetoid neoplasm assessment, 4
for HIV-associated psoriasis, 56-57 258 peripheral T-cell lymphomas,
in pregnancy, 436 Food and Drug Administration (FDA), in 123, 125
Europe clinical development of pre-Sézary syndrome, 122-123
dermatitis herpetiformis in, 375 dermatologics, 424, 427 principles and interpretation of,
herpes simplex virus in, 79 Forceps, curved, in molluscum 119-121
Kaposi's sarcoma in, 39 contagiosum removal, 89 pseudolymphoma, 123-124
Ewing’s sarcoma, evaluation of, 231 Foreign bodies, cutaneous Sjégren’s syndrome, 124
Exoderil, see Naftifine cosmetically acquired, 164-168 Genetic predisposition, to
iatrogenically acquired, 159-164 Kaposi's sarcoma, 40
F light microscopy of, 157-158 Gentamicin
Fabry’s disease, electron microscopy in occupationally acquired, 169, 172 mechanism of action of, 479-
diagnosis of, 116 radiographic studies, 157 481
Factitial dermatitis, causes of, 173-174 self-inflicted, 169, 173-174 in pregnancy, 436
Factor VIII-related antigen traumatically acquired, 168-171 for topical treatment of burns,
in immunocytochemical staining, 117 ultrastructural analysis of, 158-159 455-456
in Kaposi’s sarcoma, 40 Fortaz, see Ceftazidime Gentian violet, in pregnancy, 436,
in spindle cell tumors, 218-219, 222- Foscarnet, see Phosphonoformate 446
224 Fucidic acid, for topical treatment of GFAP, see Glial fibrillary acidic
in vascular neoplasms, 243-245 burns, 455-456 protein
FDA, see Food and Drug Administration Fucoidan, in antiretroviral therapy, 15 Gingivostomatitis, in pediatric
Feces, in iatrogenically acquired skin Fungal infections AIDS, 61
disease, 174 in AIDS Gliadin, antibodies to, in
FGF, see Fibroblast growth factor pathology of, 104-105 dermatitis herpetiformis, 300-301,
Fibrel, in wound healing, 569-571 superficial, 65 328, 417
Fibrinolysin—desoxyribonuclease, in systemic, 65-67 Glial fibrillary acidic protein
enzymatic debridement, 589 diagnosis of, 209-210, 212 (GFAP)
Fibroblast growth factor (FGF) Fungemia, in AIDS, 66 in malignant melanoma, 236
biologic activity of, 554 Fungizone, see Amphotericin B in spindle cell tumors, 222
source of, 554 Furunculosis, in pediatric AIDS, 60 Glomus tumors
Fibrohistiocytic tumors differential diagnosis of, 244
evaluation of, 217-219 G Kaposi's sarcoma resemblance
histologic appearance of, 219 Gamma globulin, bovine, in dermatitis to, 42
idealized immunophenotypes of, 219 herpetiformis, 314 Glucosidase inhibitors, in
Fibrosarcoma, therapeutic implants for, Ganciclovir antiretroviral therapy, 24
562, 564 acyclovir resistance correlated with Gluten challenge, aggressive, in
Fibroxanthoma, atypical, evaluation of, use of, 80 dermatitis herpetiformis, 305-306,
217-219 for cytomegalovirus infection, 83 406-407, 417
Finland, dermatitis herpetiformis in, 335- Gardnerella vaginalis, condyloma Gluten-free diet, for dermatitis
Clinics in Dermatology
602 SUBJECT INDEX
1992;9:595-611
herpetiformis, 295, 297-298, 301, AIDS in, 41 Herpetic folliculitis, occurrence of, 80
304-305, 307, 320, 325, 328-330, Kaposi's sarcoma in, 41 Herpetic whitlow, occurrence of, 80
371-372, 375, 380, 384, 386, 403, H antigen Hexachlorophene, in pregnancy, 436
405-407, 409-413, 415-418 in spindle cell tumors, 223 HHF35 monoclonal antibody, in spindle
Gluten-sensitive enteropathy in vascular neoplasms, 245-246 cell tumor evaluation, 218-219
dermatitis herpetiformis associated HAV, see Hepatitis A virus HHV-6, see Human herpes virus-6
with, 295-298, 300-301, 304-305, HBV, see Hepatitis B virus Hidroacanthoma (intraepidermal eccrine
307, 313-315, 317-318, 320, 325, HC! antigen poroma), histologic diagnosis of,
335, 341-344 in Kaposi's sarcoma, 40 258
environmental factors in induction of, in vascular neoplasms, 245 Histiocytosis X
301 Healing, occlusive dressing effects on, electron microscopy in diagnosis of,
Glycosylation inhibitors, in antiretroviral 576-577 116
therapy, 20 Hemangioendothelioma histologic diagnosis of, 258
Gold compounds epithelioid Histoplasma capsulatum infection, in AIDS,
chrysotherapy reinstatment and, 544 cytokeratins in, 248 66, 104-105
contraindications to, 546 differential diagnosis of, 244 Histoplasma spp., identification of, 211
in iatrogenically acquired skin spindle cell HIV, see Human immunodeficiency virus
disease,160, 163 categorization of, 218 HIV-1, see Human immunodeficiency
indications for, 545-546 evaluation of, 223-224 virus type 1
mechanisms of action of, 539-541 Hemangioma HIV-1 protease
monitoring therapy with, 544-545 differential diagnosis of, 244 antibodies to, 2
pharmacokinetics of, 536-539 laminin antibodies in, 248 post-translational modification and,
in pregnancy, 436, 446 Hemangiopericytoma 19-20
preparation and dosages for, 535-536 differential diagnosis of, 244 HLA antigens, in dermatitis
structures of, 536 therapeutic implants for, 562 herpetiformis, 301-302, 313, 318-
toxic reactions to, 541-544 Hemangiosarcoma, therapeutic implants 320, 325-327, 329, 337, 341-344,
Gold sodium thiomalate, structure of, 536 for, 562 347, 350, 352-356, 361, 365, 375,
gp 120 Hematopoietic tumors, interleukin 2 for, 380, 384
conserved amino-terminal domain of, 525-526 HLA-DRS5
2 Hemolytic anemia, Kaposi’s sarcoma in Kaposi’s sarcoma, 4, 40
rsCD4 binding to, 13-14 associated with, 41 in vascular neoplasms, 246-247
Graft copolymer starch, in osmotic Hemophilus influenzae infection, in HMB45 monoclonal antibody
debridement, 588 pediatric AIDS, 61 in immunocytochemical staining, 117
Granuloma Hemostatics, surgically-implanted, in in intraepithelial pagetoid neoplasms,
causes of, 174 iatrogenically acquired skin 257-258
histologic appearance of, 167-169, 173 disease, 162 in malignant melanoma, 237-239
therapeutic implants for, 562, 564 Henderson-Patterson bodies, in in spindle cell tumors, 218-219
Granulomatous dermatides, in HIV- molluscum contagiosum, 88-99 in vascular neoplasms, 244, 249
related atopic dermatitis, 50 Heparin, in antiretroviral therapy, 15 HMSA-2 antibody, in malignant
Granulomatous slack skin syndrome, Hepatitis, chronic active, dermatitis melanoma, 238
gene rearrangement analysis in, herpetiformis associated with, 348 Hodgkin’s disease
122-123 Hepatitis A virus (HAV), Kaposi's dermatitis herpetiformis associated
Griseofulvin sarcoma and, 39 with, 386
for dermatophyte infections, 65 Hepatitis B virus (HBV) gene rearrangement analysis in, 124
in pregnancy, 436 Kaposi's sarcoma and, 39 Holland, HIV-1 infection in, 2-3, 5
Groin, in HIV-associated seborrheic occupational exposure to, 31 Honey, in osmotic debridement, 588
dermatitis, 50 prevalence data for, 32 HPV, see Human papillomavirus
Gross cystic disease fluid protein-15 Herpes gestationis, idealized direct HSV, see Herpes simplex virus
(GCDFP-15), in Paget’s disease, immmunofluorescent findings in, Human herpes virus-6 (HHV-6),
256, 258 116 diagnosis of, 206, 211
Growth factors Herpes simplex virus (HSV) infection, Human immunodeficiency virus (HIV)
occlusive dressings and, 577-579 HIV-associated atopic dermatitis-like eruptions in, 49-
in wound healing, 553-557 in children, 61 50
clinical manifestations of, 79-80 flow cytometry of, 150-153
H diagnosis of, 205, 211 in situ hybridization in detection of,
Hair, in iatrogenically acquired skin epidemiology of, 79 131
disease, 172 interviral interactions and, 79 pathology of skin disease related to,
Hair shaft abnormalities, electron Kaposi's sarcoma and, 39 95-108
microscopy in diagnosis of, 116 Kaposi's varicelliform eruption and, 49 prevalence data for, 32
Hair thinning, in pediatric AIDS, 62 pathology of, 106 seborrheic dermatitis in, 50
Hairy leukoplakia, in AIDS, 1, 60, 100 Herpes zoster (shingles) infection, in structure of, 20
Haiti AIDS, 1, 61 syphilis in presence of, 71-73
Clinics in Dermatology SUBJECT INDEX 603
1992;9:595-611
universal safety precautions and, 31- definition of, 179 cytogenetics, 132
7 of dermatitis herpetiformis, 296, 387- development biology, 132
Human immunodeficiency virus type 1 388, 397-398 gene mapping, 132
(HIV-1) diagnostic applications of, 180-181 viral nucleic acid detection, 132-133
genome of, 20 limitations of, 181-182 background of, 129
immunologic markers for, 3 methodology of, 179-180 outline of, 130
pediatric, 59-62 Immunofluorescence antigenic mapping polymerase chain reaction compared
serologic markers for, 1-3 definition of, 182 to, 133-134
Human papillomavirus (HPV) diagnostic applications of, 183 technical aspects of, 129-130
diagnosis of, 206-207, 211 limitations of, 183-184 detection systems, 131-132
electron microscopy in diagnosis of, methodology of, 182 hybridization conditions, 131
116 transmission electron microscopy probe preparation and labeling,
genital warts associated with, 89-90 compared to, 183 130-131
intranuclear staining for, 207 Immunofluorescence studies, in slide preparation, 130
in pediatric AIDS, 61 dermatitis herpetiformis, 296-300, tissue preparation and preservation,
Hungary, dermatitis herpetiformis in, 302-303, 387, 397-398 130
343-344 Immunofluorescent findings, idealized In situ techniques, problems with, 143
Hydrocolloid powders, in osmotic direct, in diagnosis, 116 In situ transcription, characterization of,
debridement, 588 Immunogenetic factors, in dermatitis 144
Hydroquinone, topical, in iatrogenically herpetiformis, 329 Institutional review boards
acquired skin disease, 166 Immunologic markers, in course of HIV-1 advertising review of, 433-434
Hydroxychloroquine, in pregnancy, 436 infection, 3 composition of, 430
Hydroxyzine, in pregnancy, 436 Immunophenotyping history of, 429
Hyperkeratosis, in HIV-related atopic of adult T-cell lymphoma, 266-267, 270 informed consent and, 431-433
dermatitis, 50 of B-cell lymphoma, 268 procedures of, 430-431
Hyperproliferative paraneoplastic of cutaneous lymphoid infiltrates, 261- Instruments, HIV safety precautions and,
lesions, growth factors in, 555 270 33-34
Hyperthyroidism, dermatitis of cutaneous T-cell lymphoma, 263- Insulin, zinc-containing, in iatrogenically
herpetiformis associated with, 348 264 acquired skin disease, 160
future directions of, 269-270 Insulinlike growth factor 1 (IGF-1)
I immunology and, 262 biologic activity of, 554
ICP4 early protein, in herpes simplex of Ki-1 infiltrates, 267-268 source of, 554
virus, 80 of mycosis fungoides, 264-265 Interface dermatides, in HIV-related
ICRF-159 (roxazone), for Kaposi’s of pseudolymphoma, 268-270 atopic dermatitis, 50
sarcoma, 43 technique for, 261-262 Interferon a (IFN-«)
Idoxuridine, in pregnancy, 436 Immunosuppression, doxorubicin in, 555 for Kaposi’s sarcoma, 41, 43
IFN-a, see Interferon a Immunotherapy, for burns, 456-457 in prediction of progression of
IFN-t, see Interferon t Implant delivery system, for intralesional asymptomatic HIV-1 infection to
IFNs, see Interferon delivery of chemotherapeutic AIDS, 3
IgA agents, in veterinary patients, Interferon y (IFN-y)
in dermatitis herpetiformis, 295-307, 561-567 for Kaposi's sarcoma, 43
313, 315-320, 325-328, 330, 335, India ink, injected, in iatrogenically in prediction of progression of
337, 347-349, 353, 356, 362-366, acquired skin disease, 165 asymptomatic HIV-1 infection to
375-379, 383-390, 393-399, 406, Infants, timeframe for development of AIDS, 3
417 AIDS in, 1 Interferons (IFNs)
in prediction of progression of Infection, occlusive dressings and, 573, in antiretroviral therapy, 21
asymptomatic HIV-1 infection to 576 for malignant melanoma, 506-509
AIDS, 3 Inflammatory dermatoses, in AIDS Interleukin 1 (IL-1)
IGF-1, see Insulinlike growth factor 1 in children, 61-62 biologic activity of, 554
IgG antibodies, anti-HIV, appearance of, pathology of, 100 source of, 554
2 Infrared coagulators, HIV safety Interleukin 2 (IL-2)
IgM antibodies, anti-HIV, appearance of, precautions and, 34 in anticancer therapy, 523-526
2. Injected agents, in iatrogenically acquired in antiretroviral therapy, 21
IL-1, see Interleukin 1 skin disease, 164-165, 167, 174 for Kaposi’s sarcoma, 42-43
IL-2, see Interleukin 2 Ink, injected, in iatrogenically acquired in prediction of progression of
Imipramine, in iatrogenically acquired skin disease, 165 asymptomatic HIV-1 infection to
skin disease, 161 INH, for mycobacterial skin infections, 68 AIDS, 3
Immune complexes, in dermatitis Insect bites, Kaposi’s sarcoma toxicity of, 526
herpetiformis, 297-298, 300, 317 resemblance to, 42 Intermediate filaments, in malignant
Immunocytochemical stains, In situ hybridization melanoma, 236
practical, characterization of, 117 applications of Intraepidermal eccrine poroma, see
Immunoelectron microscopy cancer biology, 132 Hidroacanthoma
604 SUBJECT INDEX Clinics in Dermatology
1992;9:595-611
Intraepidermal vesicular dermatitis, in in pregnancy, 436 Leukocyte common antigen (LCA), as
AIDS, ballooning, 106-107 Ki-1 antibody, in immunophenotyping, practical immunocytochemical
Ireland, dermatitis herpetiformis in, 336, 264, 267-269 stain, characterization of, 117
370 Ki-1 lymphoma Leukocytoclastic vasculitis
Isoniazide, for bacillary angiomatosis, 76 gene rearrangement analysis in, 124 idealized direct immmunofluorescent
Isotretinoin, in pregnancy, 436 immunophenotyping of, 267 findings in, 116
Italy, dermatitis herpetiformis in, 336, Ki-67 antigen, in immunophenotyping, in pediatric AIDS, 62
343-344 264, 266 Levamisol, in burn therapy, 457
Kidney cancer, interleukin 2 for, 525 Lichenification, in HIV-related atopic
J Kidney disease, dermatitis herpetiformis dermatitis, 50
Japan associated with, 347-349 Lichen planus
dermatitis herpetiformis in, 375 Klebsiella pneumoniae dermatitis herpetiformis associated
linear IgA bullous dermatosis in, 388 ciclopirox against, 473 with, 348, 356
clotrimazole against, 473 Kaposi’s sarcoma resemblance to, 42
K miconazole against, 473 Lidocaine hydrochloride, in pregnancy,
4KB5 antibody, in immunophenotyping, Kwashiorkor, in pediatric AIDS, 62 436, 446
270 Light microscopy
Kaposi's sarcoma L of cutaneous foreign bodies, 157-158
bacillary angiomatosis differentiated Laboratory markers, as predictors of of dermatitis herpetiformis, 290-291
from, 76 progression from asymptomatic Linear IgA bullous dermatosis
categorization of, 218 HIV-1 infection to AIDS, 1-5 of adults, 383-390
clinical manifestations of B-Lactoglobulin, in dermatitis atypical cases of, 385-386
allograft-associated Kaposi's herpetiformis, 314 autoimmune diseases and, 386
sarcoma, 39 Lambda-carrageenan, in antiretroviral clinical characteristics of, 383-385
classic Kaposi’s sarcoma, 39-40 therapy, 15 circulating anti-basement
endemic Kaposi’s sarcoma, 39-41 Laminin monoclonal antibody, in membrane zone antibodies of IgA
epidemic Kaposi’s sarcoma, 39, 41 vascular neoplasms, 248 class in, 387
renal transplant-associated Kaposi’s Lamisil, see Terbinafine differential diagnosis of, 384
sarcoma, 39, 41, 62 LAMMA, see Laser microprobe mass genetics of, 388
cytomegalovirus infection and, 82 analysis histopathology of, 386-387
differential diagnosis of, 42 Large plaque parapsoriasis, gene historical review of, 383
etiology and pathogenesis of, 39-40 rearrangement analysis in, 122- immune deposits in, 387
evaluation of, 223-224 123 immunoelectronmicroscopic
historical aspects of, 39 Laser microprobe mass analysis studies of, 387-388
HLA-DR5S associated with, 4, 40 (LAMMA), of cutaneous foreign internal malignancies and, 386
idealized immunophenotypes of, 219 bodies, 159, 169 pathogenesis of, 389
laboratory findings in, 41-42 Laser therapy therapy for, 389-390
nodular stage of, 97 for condyloma acuminatum, 91 unclassified cases of, 387-388
patch lesions of, 96 HIV safety precautions and, 34 of childhood
pathology of, 42, 95-96 for verrucae vulgaris, 91 childhood cicatricial pemphigoid
in pediatric AIDS, 62 LCA, see Leukocyte common antigen relationship to, 398-399
plaque lesions of, 97 Lectins clinical characteristics of, 393-396
prognosis for, 43 in spindle cell tumors, 218-219, 223- frequency as compared with other
spindle cell proliferation in, 97 224 bullous diseases of children and
staging of, 42 in vascular neoplasms, 244, 246 adults, 393-394
treatment of, 42-43 Leiomyosarcoma histopathology of, 396-397
Kaposi's varicelliform eruption, herpes categorization of, 217-218 historical review of, 393
simplex virus in, 49 differential diagnosis of, 244 immune deposits in, 397-398
Kappa-carrageenan,in antiretroviral evaluation of, 221-224 immunopathology of, 396-
therapy, 15 histological appearance of, 223 397
Karaya gum powder, in osmotic idealized immunophenotypes of, 219 pathogenesis of, 399
debridement, 588 Leishmaniasis, diagnosis of, 211-213 therapy for, 399
Keflex, see Cephalexin Leprostatic agents, in iatrogenically Lipoxygenase inhibitors, for HIV-
Kefurox, see Cefuroxime acquired skin disease, 161 associated psoriasis, 56
Kefzol, see Cefazolin Leu series antigens, in Lips, herpes simplex virus lesions
Keratin, in intraepithelial pagetoid immunophenotyping, 264, 266 of, 80
neoplasm assessment, 258 Leu7 monoclonal antibody, in spindle cell Liquid nitrogen therapy
Ketoconazole (Nizoral) tumor evaluation, 218-219, 222- HIV safety precautions and, 34
for coccidiomycosis, 67 223 for molluscum contagiosum, 89
for dermatophyte infections, 65 Leukemia Listeria monocytogenes
for mucocutaneous candidiasis, 65 flow cytometry of, 154 ciclopirox against, 473
for paracoccidiomycosis, 67 immunophenotyping of, 266-267 clotrimazole against, 473